Stemline Therapeutics elects Kevin Buchi to board
This article was originally published in Scrip
Executive Summary
Stemline Therapeutics, a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target cancer stem cells and tumour bulk, has appointed Kevin Buchi to its board of directors. Mr Buchi, who was previously CEO of Cephalon before its acquisition by Teva Pharmaceutical Industries, now serves as corporate vice-president of global branded products for Teva.